Test Code LABP2Y12 Platelet P2Y12 Inhibition Test
Clinical Information
To determine the degree of platelet inhibition from the use of P2Y12 inhibition drug therapies known as thienopyridines. These include Clopidogrel (Plavix), Prasugrel, Ticlopidine (Ticlid), and Ticagrelor.
Synonym
- P2Y12
- Clopidogrel Inhibition
- Ticagrelor Inhibition
Specimen Required
Preferred Container/Tube: 2 - Greiner Partial Vacuum 3.2% Sodium Citrate tubes
Acceptable Container/Tube: 2 - Greiner Partial Vacuum 3.2% Sodium Citrate tubes
Specimen Volume: 2 properly filled tubes
Specimen Minimum Volume: 2 properly filled tubes
Collection Instructions: Prior to filling, 2 mL of blood must be drawn into a non-additive discard tube.
Specimen Collection Information
Test Not Available to Outreach locations. Outpatient sample collection is available at the OSU Ross Laboratory ONLY. Special collection tube requirements/ limited specimen stability. A requisition or order, with physician signature and diagnosis code required.
Specimen Stability Information
Ambient: 4 hours
Rejected Due To
- Ambient specimens >4 hours old
- Samples improperly centrifuged
- Samples sent in pneumatic tube system (PTS)
- Underfilled or overfilled tube
- Samples collected without discard tube
- Unacceptable container type
Reference Values
194-418 PRU
Interpretation
Test results are reported in P2Y12 Reaction Units (PRU). The pre-drug Normal Reference Range is 194 - 418 PRU. PRU measures the extent of platelet aggregation in the presence of P2Y12 inhibitor drugs such as clopidogrel (Plavix), prasugrel (Effient), ticlopidine (Ticlid), and ticagrelor (Brilinta).
Cautions
Patients who have been administered glycoprotein IIb/IIIa inhibitors tirofiban (Aggrastat) or eptifibatide (Integrilin) within the last 2 days or abciximab (ReoPro) within the last 2 weeks should not be tested. Platelet counts less than 119K or more than 502K, and Hematocrit values less than 33% or greater than 52% can interfere with testing and valid results may not be obtained.
The P2Y12 Platelet Function assay is not intended for use with inherited platelet disorders such as von Willebrand Factor Deficiency, Glanzmann Thrombasthenia and Bernard-Soulier Syndrome.
Method Description
Whole blood platelet aggregometry based on the ability of activated platelets to bind fibrinogen. Fibrinogen-coated microparticles aggregate in whole blood in proportion to the number of expressed platelet GP IIb/IIIa receptors.
Performing Lab
Clinical Lab UH
Day(s) Performed
Monday through Sunday
Report Available
Same day/1 day
Reporting Name
Platelet P2Y12 Inhibition Test
CPT Code Information
85576
LOINC Code Information
53813-2